Shopping Cart
- Remove All
Your shopping cart is currently empty
Brontictuzumab
🥰Excellent
Catalog No. T76785Cas No. 1447814-75-6
Alias OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant Antibody
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.
Brontictuzumab
Brontictuzumab
🥰Excellent
Catalog No. T76785Alias OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant AntibodyCas No. 1447814-75-6
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $297 | In Stock | |
| 5 mg | $775 | In Stock | |
| 10 mg | $1,230 | In Stock | |
| 25 mg | $1,830 | In Stock | |
| 50 mg | $2,480 | In Stock | |
| 100 mg | $3,330 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Brontictuzumab"
Valproic Acid
Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedCarvacrol
O-Thymol, Karvakrol, cymophenol
T4S1990499-75-2
1. Carvacrol (O-Thymol) presents anxiolytic effects. 2. 5-Isopropyl-2-methylphenol presents antinociceptive activity. 3. Carvacrol presents antidepressant effects, seems to be dependent on its interaction with the dopaminergic system, but not with the serotonergic and noradrenergic systems.
- $42
Size
QTY
CB-103
T12246218457-67-1
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity.
- $33
Size
QTY
Tangeretin
Tangeritin, NSC618905, NSC53909
T2842481-53-8
Tangeretin (NSC-618905), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models and was also selected as a Notch-1 inhibitor.
- $47
Size
QTY
Aβ42-IN-2
T96411914989-80-2In house
Aβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research [1].
- $35
Size
QTY
RO7185876
T397022226038-71-5In house
RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.
- $293
Size
QTY
Gossypolone
T319874547-72-2In house
Gossypolone is is a proposed major metabolite of gossypol. Gossypolone reduces Notch/Wnt signaling and induces apoptosis.
- $195
Size
QTY
gamma-secretase modulator 1
N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4-phenyl-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine
T113581172637-87-4In house
gamma-secretase modulator 1 is a modulator of γ secretase and can be used in studies about the treatment of Alzheimer's disease.
- $30
Size
QTY
DAPT Cited
LY-374973, GSI-IX
T6202208255-80-5
DAPT (LY-374973) is a γ-secretase inhibitor that inhibits total Aβ and Aβ42 (IC50=115/200 nM) and is orally active. DAPT is also a Notch inhibitor. DAPT induces cell differentiation, autophagy and apoptosis.
- $53
Size
QTY
CitedFLI-06 Cited
FLI 06
T3075313967-18-9
FLI-06 is a Notch signaling inhibitor (EC50: 2.3 μM).
- $30
Size
QTY
CitedIMR-1A Cited
T3540331862-41-0
IMR-1A is the metabolite of IMR-1 which is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μMol/L.
- $68
Size
QTY
CitedSelect Batch
Concentration:8.63 mg/mL
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway. It has antitumor activity, inhibits tumor cell proliferation, and can be used in the study of leukemias and lymphomas. |
| In vitro | 0-100 μg/mL Brontictuzumab effectively inhibited the activity of Notch1 signaling pathways, including DLL4 and JAG1/2. In HPB-ALL cell line, treatment with 25 μg/mL Brontictuzumab for 4 days significantly reduced the level of Notch1 intracellular structural domain. [1] In MCL cells, treatment with 25 μg/mL Brontictuzumab for 48 hours inhibited DLL4-mediated overexpression of cleaved Notch1. In addition, the increased phosphorylation of MEK and ERK in Mino cells caused by DLL4 stimulation was effectively blocked. [2] |
| In vivo | In the MCL model, 20 mg/kg Brontictuzumab intraperitoneal injection, administered every 4 days, inhibited DLL4-induced Notch1 activation. [2] Intraperitoneal injection of 15 mg/kg Brontictuzumab significantly reduced tumor burden in a T-ALL xenograft model. [3] |
| Alias | OMP52M5, OMP 52M5, Anti-Human NOTCH1 Recombinant Antibody |
| Cas No. | 1447814-75-6 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Brontictuzumab | purchase Brontictuzumab | Brontictuzumab cost | order Brontictuzumab | Brontictuzumab in vivo | Brontictuzumab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.